Pathology: es-BC - HER2 positive - (neo)adjuvant (NA); la/mBC - HER2 positive - 2nd Line (L2);
| es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 2nd Line (L2) | |||||
| KATHERINE, 2019 | Harbeck (TDM-1), 2017 | Harbeck (TDM1 plus ET), 2017 | DESTINY Breast03, 2022 | EMILIA, 2012 | ||
| trastuzumab emtansine | 3 | T1 | T1 | T0 | T1 | |
| trastuzumab deruxtecan | 1 | T1 | ||||
| trastuzumab emtasine plus endocrine therapy | 1 | T1 | ||||
| trastuzumab | 0 | T0 | ||||
| trastuzumab plus endocrine therapy | 0 | T0 | T0 | |||
| lapatinib plus capecitabine | 0 | T0 | ||||